文献速递神经免疫

利妥昔单抗每6个月与每12个月给药在复发型多发性硬化中的比较效果

Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
PubMed 文献 · Neurology · 2025-12-22

本研究采用目标试验模拟法,基于2008至2023年Kaiser Permanente南加州队列,比较复发型多发性硬化患者在接受利妥昔单抗500 mg治疗稳定1年后,改为每12个月给药与继续每6个月给药对疾病活动复发风险的影响。结果显示,延长给药间隔至每12个月虽伴随更明显的B细胞再增殖,但未增加NEDA-3失败风险(ITT HR 1.60,95%CI 0.69-3.68;PP HR 1.44,95%CI 0.45-4.61)。

要点

  • 稳定1年后将利妥昔单抗500 mg延长至每12个月给药未增加疾病活动风险。
  • 每12个月给药组B细胞再增殖更常见,但未转化为NEDA-3失败风险升高。
  • 结果为IV级证据,支持在稳定患者中考虑延长给药间隔。

核心结论

  • 在利妥昔单抗治疗第一年达到NEDA-3的复发型多发性硬化患者中,将500 mg剂量间隔延长至每12个月与继续每6个月相比未增加疾病活动复发风险。

研究设计与样本

  • 采用目标试验模拟法,基于2008至2023年Kaiser Permanente南加州回顾性队列,纳入140例每12个月给药和468例每6个月给药患者,中位ITT随访分别为2.6年和3.9年。

主要发现

  • 每12个月给药组B细胞再增殖(≥80 cells/μL)在PP分析中为70.5%、ITT分析中为75.7%,每6个月组分别为23.3%和60.2%。
  • 截至4年,NEDA-3失败在倾向评分调整ITT分析中HR为1.60(95%CI 0.69-3.68),PP分析中HR为1.44(95%CI 0.45-4.61)。
  • 复发和/或MRI疾病活动(3.5%)及NEDA-3失败(3.8%)在4年内不常见。

临床怎么用

  • 对于利妥昔单抗治疗第一年达到NEDA-3的复发型多发性硬化患者,可考虑将500 mg剂量间隔延长至每12个月以降低累积剂量和感染风险。

局限性

  • 本研究为IV级证据,采用回顾性队列和目标试验模拟设计,可能存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Rituximab (RTX) dosed every 6 months is an affordable and highly effective treatment for relapsing multiple sclerosis (RMS). However, higher cumulative doses are associated with greater risks of infections. Whether extending dosing intervals at a low dose (500 mg) increases the risk of return of disease activity, particularly in those with only 1 year of stability or with significant return of B cells, is uncertain. Our objective was to compare whether extending RTX dosing to every 12 months (q12mo) vs continuing every 6 months (q6mo) dosing in patients with RMS increased the risk of return of disease activity. METHODS: We emulated a target trial comparing the effectiveness of RTX 500 mg q12mo to q6mo starting in year 2 (baseline) among patients with RMS who had active disease at RTX start and no evidence of disease activity (NEDA) during the first year on RTX. Eligible patients were identified from the retrospective cohort of patients with MS treated with RTX between 2008 and 2023 in Kaiser Permanente Southern California. The absence of relapses, MRI disease activity, and disability progression (NEDA-3) were analyzed by intention-to-treat (ITT) and per-protocol (PP) with inverse probability of treatment weighting of receiving q6mo or q12mo dosing. RESULTS: We identified 140 patients (mean age 40.4 years, 73.6% female) who received q12mo dosing and 468 patients (mean age 38.4, 70.9% female) on q6mo dosing after baseline with a median ITT follow-up of 2.6 (interquartile range [IQR] 1.9-3.3) and 3.9 years (IQR 2.4-4.8), respectively. Relapses and/or MRI disease activity (3.5%) and failing NEDA-3 (3.8%) up to 4 years later were uncommon. Extending dosing to q12mo was associated with significant B-cell repopulation (70.5% with ≥80 cells/μL PP, 75.7% ITT) compared with q6mo intervals (23.3% with ≥80 cells/μL PP, 60.2% ITT) but not with an increased risk of failing NEDA-3 up to 4 years after baseline in propensity score-adjusted ITT (hazard ratio [HR] 1.60, 95% CI 0.69-3.68) or PP analyses (HR 1.44, 95% CI 0.45-4.61). DISCUSSION: Extending low-dose RTX treatment intervals after 1 year of stability to q12mo was highly effective and did not result in an increased risk of disease activity despite high B-cell counts compared with continuing q6mo dosing over 2 or more years of follow-up. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in persons with RMS with NEDA-3 in the 12 months following RTX, extending the dosing interval to 12 months did not increase the risk of disease activity compared with continuing q6mo dosing.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Langer-Gould A, Li BH, Smith JB, et al. Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2025. PMID: 41428985. doi:10.1212/WNL.0000000000214473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。